Senseonics Holdings Inc. will soon begin marketing its Eversense continuous glucose monitoring (CGM) system in the US as an alternative to fingerstick testing to help patients make diabetes treatment decisions throughout the day.
On 6 June, the US Food and Drug Administration approved a PMA supplement for new “non-adjunctive” labeling stating that Eversense...